Food and Drug Administration. (a) Pursuant to 21 C.F.R. § 314.94(a)(12)(v), and within 10 business days after the Commencement Date, IMPAX shall submit to the FDA, with a copy to the Purdue Companies, a statement that IMPAX has been granted a license with respect to the Purdue Patents with respect to the IMPAX Product, pursuant to the terms of this Supplemental License Agreement.
Appears in 3 contracts
Samples: Supplemental License Agreement (Impax Laboratories Inc), Supplemental License Agreement (Impax Laboratories Inc), Supplemental License Agreement (Impax Laboratories Inc)
Food and Drug Administration. (a) Pursuant to 21 C.F.R. § 314.94(a)(12)(v), and within 10 business days after the Commencement Signing Date, IMPAX shall submit to the FDA, with a copy to the Purdue Companies, a statement that IMPAX has been granted a license with respect to the Purdue Patents with respect to the IMPAX Product, pursuant to the terms of this Supplemental Patent License Agreement.
Appears in 3 contracts
Samples: Patent License Agreement (Impax Laboratories Inc), Patent License Agreement (Impax Laboratories Inc), Patent License Agreement (Impax Laboratories Inc)
